E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Not applicalbe |
Esclerosis múltiple remitente recurrente |
|
E.1.1.1 | Medical condition in easily understood language |
Not applicable |
Esclerosis múltiple remitente recurrente |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10028245 |
E.1.2 | Term | Multiple sclerosis |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Verificar la posible asociación entre parámetros farmacodinámicos y acontecimientos adversos en el escalado de dosis inicial del tratamiento |
|
E.2.2 | Secondary objectives of the trial |
Objetivos secundarios: Los objetivos secundarios son: ? Determinar la posible influencia de la dosis según el índice de masa corporal. ? Determinar si alguna reacción adversa se asocia con un parámetro farmacodinámico |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. El paciente tiene EM recidivante 2. Asignación a un protocolo de tratamiento con interferón beta-1a a dosis altas. 3. Edad entre 18 y 60 años 4. El paciente tiene una puntuación en la EDSS <5,5. 5. Uno o más brotes en el año previo. 6. Contracepción eficaz. |
|
E.4 | Principal exclusion criteria |
1. EM primaria progresiva o EM secundaria progresiva sin recidivas superpuestas. 2. Tratamiento previo con interferón beta (beta-1b o beta-1a) 3. Embarazo o lactancia. 4. Tratamiento previo con inmunomoduladores o inmunosupresors. 5. Alteraciones hematológicas o hepáticas importantes (clínicas o analíticas) 6. Enfermedad importante que interfiera con la valoración del estudio o con la realización del mismo. 7. Participación simultánea en otro estudio experimental. 8. Alergia conocida al producto o a sus excipientes. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
El parámetro principal es la asociación (positiva o negativa) entre los parámetros farmacodinámicos y la presencia de acontecimientos adversos. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Days 14, 28 and 56 |
Días 14, 28 y 56 |
|
E.5.2 | Secondary end point(s) |
La posible asociación relevante, positiva o negativa (r > 0.5 ó < -0.5), entre marcadores farmacodinámicos y acontecimientos adversos, se precisará el nivel plasmático de cada uno de los marcadores biológicos (beta2-microglobulina, neopterina, 2?5? OAS), así como cada uno de las reacciones adversas más frecuentes clínicas (síndrome gripal, dolor de cabeza) y analíticas (aumento de las transaminasas, disminución de los leucocitos y plaquetas). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 12 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Not applicable |
Cierre de la base de datos |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |